107 results about "Akt signalling" patented technology

The invention discloses the application of an IL-11 monoclonal antibody in inhabiting a PI3K/Akt signal channel. The concentration of the IL-11 monoclonal antibody is 8 mug/mL, and the dosage of the IL-11 monoclonal antibody is 10 mug. The safe and efficient PI3K/Akt signal channel inhibitor, namely the IL-11 monoclonal antibody is found, and can be specifically combined with IL-11 secreted by cells to induct PTEN transcription, up-regulate PTEN expression and inhibit the expression of AKT on the downstream portion of the PI3K/Akt signal channel, and then the whole signal channel is inhibited. The inhibitor is a natural antibody, so that toxic and side effects are reduced and safety and efficiency are high.

The invention discloses CXCL13 oncoprotein and an application of targeted medicine for the CXCL13 oncoprotein in the tumor aspect. A method for preparing the tumor targeted medicine includes the steps of screening antibodies capable of effectively reducing the high expression of the CXCL13 oncoprotein or neutralizing the activity of the CXCL13 oncoprotein; preparing the corresponding tumor targeted medicine through the antibodies. According to the CXCL13 oncoprotein and the application, the anti-CXCL13 monoclonal antibodies can achieve the good anti-tumor effect by suppressing a p-AKT signal channel, a p-ERK signal channel and an EMT signal channel and accordingly suppressing growth, invasion and metastasis of tumor cells.

The present invention discloses the use of selenate or its pharmaceutically acceptable salts, especially in supranutritional amounts, in methods and compositions for inhibiting the growth or proliferation of tumor cells. The present invention also discloses the use of selenate or its pharmaceutically acceptable salts in combination with one or both of a hormone ablation therapy and a cytostatic agent or cytotoxic agent, for inhibiting the growth or proliferation of tumor cells. In certain embodiments, the methods of the invention are useful for treating or preventing cancers, especially cancers in which the Akt signaling pathway is activated, such as prostate cancer. Additionally, the present invention discloses the use of selenate or its pharmaceutically acceptable salts in combination with a hormone-ablation therapy and optionally a cytostatic agent or cytotoxic agent in methods and compositions for treating hormone- dependent cancers.

The invention discloses a function and application of SH2B adapter protein 3(SH2B3) for treating cardiac hypertrophy. By virtue of the SH2B adapter protein 3(SH2B3), interrelation between the expression of SH2B3 gene and cardiac hypertrophy is determined; when the cardiac hypertrophy occurs, the expression of SH2B3 is obviously increased; activation of an Akt signal channel is suppressed by SH2B3 gene defect, the cardiac hypertrophy and fibrosis are also suppressed, and the heart function is protected; the activation of the Akt signal channel is remarkably accelerated by over expression of the SH2B3 gene, the cardiac hypertrophy and fibrosis are improved, and the heart function is deteriorated. Therefore, the SH2B3 gene can be used as a medicine target mark for screening medicines for protecting the heart function and/or preventing, relieving and/or treating the cardiac hypertrophy; the SH2B3 gene can be used as a target gene in gene treatment for designing and preparing medicines and/or biological reagents for protecting the heart function and/or preventing, relieving and/or treating the cardiac hypertrophy, so that an effective novel way is provided for the treatment of the cardiac hypertrophy.

The invention provides a polypeptide for targeting a liver cancer vascular endothelial cell and application thereof. The polypeptide is characterized by comprising an amino acid sequence of SPSCALP. The polypeptide SPSCALP provided by the invention can target the liver cancer vascular endothelial cell, is used for mainly inhibiting a PI3K-AKT signal path of the liver cancer vascular endothelial cell and inhibiting the biological function of the liver cancer vascular endothelial cell, but has no remarkable influence on normal liver tissue endothelial cells.

The invention belongs to the fields of biotechnology and medicine, and in particular relates to an application of an SET gene in preparing a product for diagnosing and/or treating gastric cancer. It is provided that the SET achieves frequent high expression (80%) in gastric cancer tissues, and the increase in SET expression is significantly correlated to aggressive phenotype and worse prognosis of a patient with the gastric cancer (P is less than 0.05). The low expression of the SET can obviously inhibit the migration and the invasion of gastric cancer cells. In addition, the SET, by virtue of a PP2A/Akt signaling pathway, can promote tumor malignant transformation. Furthermore, the gastric cancer tissues are obviously higher than para-carcinoma tissues in SET protein level. Therefore, the SET gene can serve as a specific marker gene for diagnosing the gastric cancer, so that it is more accurate and rapid to diagnose the gastric cancer. The SET gene provided by the invention provides a novel therapeutic target for the prevention and the treatment of the gastric cancer.

The invention belongs to the technical field of medicines, and relates to new medicinal application of andrographolide, in particular to new application of the andrographolide in preparation of medicines for treating spongioblastoma. The andrographolide can restrain the growth of human spongioblastoma cells in vivo and in vitro, the mechanism of the andrographolide relates to down regulation of activation of a PI3K/Akt signal, and then human andrographolide cell cycles are induced to be retarded in a G2/M period. The andrographolide can be used for preparing intestinal canal and parenteral administration dosage forms and is used for treating human spongioblastoma.

The invention provides a method for enhancing the secretion function of mesenchymal stem cells and application, and belongs to the technical field of biology. Research shows that by using Hyaluronic acid sodium (HA) to pretreat umbilical cord mesenchymal stem cells in vitro, the secretion function of the umbilical cord mesenchymal stem cells can be significantly promoted, secretion of HGF, SCF, EGF, VEGF and other factors is promoted, activation of a PI 3K-AKT signal channel is further promoted, and the repair effect on damage is enhanced. The method is simple, convenient, low in cost and highin safety, and therefore the method HAs good practical application value.

The invention discloses application and a detection method of an LINC02085 gene, and belongs to the technical field of molecular biology of rheumatism. According to the invention, a specific PCR primer is designed and synthesized according to the extracted total RNA sequence, and an Rt-qPCR technology is utilized to find that the expression of LINC02085 in peripheral blood mononuclear cells of a rheumatoid arthritis (RA) patient is significantly increased, which proves that the LINC02085 can be applied to the preparation of a preparation for auxiliary diagnosis, treatment or prognosis evaluation of rheumatoid arthritis. The pcDNA3.1-LINC02085 sequence for specific overexpression of the gene and the si-LINC02085 sequence for small interference of the gene are designed and synthesized at thesame time, proliferation of synovial fibroblasts (FLS) and inflammatory response of FLS induced by TNF-alpha can be remarkably inhibited by regulating and controlling a PI3K/AKT signal channel, and the gene can become a molecular targeted therapy tool for RA.

There is provided a method for promoting epithelium repair in a subject, the method comprising administering to the subject a therapeutically effective amount of an activator of PI3K/Akt signalling.

The invention discloses a drug composition for treating B cell lymphoma. The drug composition comprises a PI3K/AKT signal pathway inhibitor and a chemotherapeutic drug, and further comprises targetedCD20 infliximab, such as rituximab. The drug composition provided by the invention is especially suitable for treating relapsed or refractory B cell lymphoma. In view of the key effect of a CSC (cancer stem cell) in the transferring and drug resisting process, the invention provides a new pro-differentiation therapy strategy for the CSC, that is, a decisive signal conduction pathway for maintaining the dryness of the stem cell is determined, and then the pathway is interfered to promote CSC differentiation. The differentiation cell is finally sensitive to a routine treatment method (such as chemotherapy). Under the condition, the PI3K/AKT signal pathway inhibitor is combined with an R-CHOP scheme to exert a good effect of treating drug-resisting DLBCL (diffuse large B cell lymphoma).

The invention discloses a traditional Chinese medicine preparation, and preparation and application thereof. The traditional Chinese medicine preparation is prepared from the following raw materials in proportion by mass: 10 to 30 parts of prepared rehmannia roots, 10 to 30 parts of radix rehmanniae, 3 to 6 parts of cortex cinnamomi, 10 to 20 parts of radix salviae miltiorrhizae, 10 to 20 parts of radix angelicae sinensis, 10 to 20 parts of seeds of Chinese dodder, 10 to 20 parts of fructus psoraleae, 10 to 20 parts of herba epimedii, 9 to 30 parts of radix pseudostellariae, 10 to 15 parts of radix polygoni multiflori preparata, 8 to 15 parts of radix paeoniae rubra, 9 to 15 parts of cortex moutan, 9 to 15 parts of poria cocos, 9 to 15 parts of bighead atractylodes rhizome, 15 to 30 parts of Chinese yam and 3 to 6 parts of liquorice roots. The traditional Chinese medicine preparation has the advantages that the bone marrow mesenchymal stem cell multiplication of an AA patient can be promoted; by activating an SDF-1/CXCR4-PI3K/AKT signal path, the aplastic anemia MSCs function restoration can be effectively promoted; the mRNA expression of MSCs VEGF, SDF-1, CXCR4 and Akt of mice can be effectively improved; the hemopoietic microenvironment can be improved.